Sökning: "CXCL12"
Visar resultat 16 - 20 av 30 avhandlingar innehållade ordet CXCL12.
16. Mesenchymal niche contribution to normal and malignant hematopoiesis
Sammanfattning : Normal hematopoiesis is tightly regulated by hematopoietic microenvironment/niche in bone marrow (BM) via direct hematopoietic cell-niche cell interaction and factors secreted by various types of cellular niches. The BM niche consists of cells of mesenchymal cell origin including mesenchymal stem cells (MSCs) and progenitor cells (MPCs). LÄS MER
17. T Cell Ontogeny and Effector Functions in Galphai2-deficient Colitis
Sammanfattning : Inflammatory bowel disease (IBD) comprising Crohn s disease and ulcerative colitis is a disease that affects millions of people worldwide, especially in northern countries such as Sweden, and is characterised by chronic uncontrolled inflammation of the intestinal mucosa. It is the general belief that multiple factors such as genetic and environmental aspects are involved in disease pathogenesis. LÄS MER
18. Molecular determinants of glioma subsets with distinct histology or sensitivity to signal transduction inhibitors
Sammanfattning : Gliomas are brain tumors that currently are treated with surgery, radiation and chemotherapy. Less than 7.5% of patients with GBM survive more than 2 years after diagnosis. LÄS MER
19. Compartmentalisation of the immune response in human skin : cross-talk between dendritic cells and T cells in healthy conditions and in psoriasis
Sammanfattning : Human skin is highly compartmentalised and distinct subsets of dendritic cells (DCs) and T cells reside in epidermis and dermis. Alterations in the composition of DCs and T cells have been observed in psoriasis, a common cytokine-driven focal inflammatory skin disease. LÄS MER
20. The role of cannabinoid receptors, G alpha z, and B cell receptor in lymphoma pathobiology with focus on chemotaxis
Sammanfattning : Mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL) are two incurable B cell malignancies, with an overall survival of 5 to 8 years and 6 to 10 years, respectively. Therapies are available but are often very aggressive, and patients relapse due to minimal residual disease. LÄS MER